Eli Lilly stock gains as strong demand lifts sales outlook

Eli Lilly reported strong third-quarter growth on October 29, 2026, and raised its full-year sales outlook. The company said in its official results release that demand for Mounjaro and Zepbound drove the increase.

Eli Lilly stock traded at EUR 1,295.70 on Lang & Schwarz at 16:09 CET on Thursday, November 5, 2026, 1.70 percent above the Xetra close of Wednesday, November 4, at EUR 1,274.00. The quote was 1.38 percent above the EUR 1,278.00 price in the latest relevant report published earlier on November 5 at 08:19 CET.

What changed since the last report

Worldwide third-quarter revenue rose 39 percent year over year to USD 24.4 billion. Volume increased 53 percent, while realized prices declined 15 percent, according to Lilly. Key product revenue reached USD 17.1 billion, led by the two tirzepatide brands.

Mounjaro revenue increased 65 percent to USD 10.7 billion, while Zepbound revenue rose 49 percent to USD 5.35 billion. Lilly also pointed to growth in oncology, immunology and neuroscience and to the global launch of Foundayo.

Higher sales outlook, lower EPS range

Lilly lifted its 2026 revenue guidance to USD 91 billion to USD 92 billion from USD 85 billion to USD 87 billion. The company said underlying non-GAAP EPS guidance improved by USD 4.07 per share at the midpoint, but acquired in-process research and development charges of USD 4.57 per share more than offset that increase. The updated adjusted EPS range is USD 35.00 to USD 36.00, compared with USD 35.50 to USD 36.50 previously.

The release also highlighted approximately USD 900 million of third-quarter benefits, including USD 410 million from Jardiance milestones and favorable rebate and discount adjustments. That mix matters for investors because reported growth includes items that may not recur.

Investors can follow the real-time quote of Eli Lilly and Company stock as the market weighs demand, pricing and manufacturing execution.

Next test for the growth thesis

The December quarter is the next operating test for the higher annual revenue range. Lilly's pipeline and regulatory progress add longer-term potential, but the raised sales target also increases the execution burden.

The S&P 500 provides the broader market backdrop for US-listed Eli Lilly stock. More news and analyses on Eli Lilly and Company stock.